ASCO Annual Meeting: Genitourinary | Conference

Petros Grivas, MD, PhD, on the Impact of First-Line Maintenance Avelumab in Advanced Urothelial Carcinoma
June 18, 2021

Petros Grivas, MD, PhD, discusses the impact of avelumab on patients with advanced urothelial carcinoma in the first-line maintenance setting.

Robert A. Figlin, MD, Discussed How New Findings Support Cabozantinib as Second-Line Standard in RCC
June 10, 2021

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss results of the CANTATA trial of cabozantinib with or without telaglenastat.

Abiraterone Plus ADT and Docetaxel to Treat de novo mCSPC Improved rPFS
June 09, 2021

adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free survival for men with de novo metastatic castration-sensitive prostate cancer.